A phase II trial of atezolizumab + carboplatin + etoposide with liver-directed radiotherapy in extensive stage small cell lung cancer (ES-SCLC) patients with liver metastases
Liver-Directed Radiotherapy Along with Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Liver Metastases
Sponsor: Genentech
Enrolling: Male and Female Patients
IRB Number: AAAT0174
U.S. Govt. ID: NCT04923776
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate whether radiation treatment directed at liver metastases can be safely added to standard of care treatment for extensive-stage small cell lung cancer (ES-SCLC). The current standard treatment for people who have ES-SCLC is chemotherapy, called carboplatin and etoposide, that is combined with a type of immunotherapy called atezolizumab. However, patients with liver involvement of their ES-SCLC don't respond as well to this treatment. The study aims to answer whether adding radiation directed at liver metastases can improve responses to standard chemoimmunotherapy in this patient population. All study participants will get the same study intervention, which will be chemoimmunotherapy and radiation therapy.
Brian Henick, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have confirmed extensive stage small cell lung cancer (ES-SCLC)? Yes No
Have you had prior treatment for extensive stage small cell lung cancer (ES-SCLC)? Yes No
Do you have at least one liver metastasis? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator